2016 Hematological Malignancies

ECHELON-1: Phase III Trial BV + AVD vs. ABVD in frontline advanced cHL

Brentuximab Vedotin 1,2 mg/kg q2w + AVD 28-day cycles

R A N D O M I

E V A L U A T

I O N

Z E

ABVD 28-day cycles

* Assessment based on Revised Response Criteria for Malignant Lymphoma

Younes et al, ASCO 2013; Chicago, US (Abstract #TPS8612)